Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer (2024)

1. http://orcid.org/0000-0002-5494-8775Eric Rios-Doria1,
2. http://orcid.org/0000-0001-9689-1298Nadeem R Abu-Rustum1,2,
3. Kaled M Alektiar3,
4. Vicky Makker4,5,
5. Ying L Liu4,5,
6. Dmitriy Zamarin4,5,
7. Claire F Friedman4,5,
8. Carol Aghajanian4,5,
9. Lora H Ellenson6,
10. http://orcid.org/0000-0001-9698-0936Sarah Chiang6,
11. Britta Weigelt6,
12. http://orcid.org/0000-0003-0365-7510Jennifer J Mueller1,2 and
13. http://orcid.org/0000-0003-0818-3836Mario M Leitao1,2

1. ¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
2. ²Department of OB/GYN, Weill Cornell Medical College, New York, New York, USA
3. ³Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
4. ⁴Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
5. ⁵Department of Medicine, Weill Cornell Medical College, New York, New York, USA
6. ⁶Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA

1. Correspondence to Dr Mario M Leitao, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA; leitaom{at}mskcc.org

• Endometrial Neoplasms
• Uterine Cancer

• Endometrial Neoplasms
• Uterine Cancer

Footnotes

• X @RiosDoriaMD, @leitaomd

• Contributors ER-D: conceptualization, data curation, formal analysis, methodology, and writing–review and editing. NRA-R, KA, VM, YLL, DZ, CFF, CAA, LE, SC, and BW: writing–review and editing. JM: conceptualization, data curation, formal analysis, methodology, writing–original draft, and writing–review and editing. ML: conceptualization, formal analysis, methodology, and writing–review and editing, guarantor.

• Funding Research reported in this publication was supported in part by a National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Support Grant (P30 CA008748). BW is supported in part by Cycle for Survival, NIH/NCI (P50 CA247749), and Breast Cancer Research Foundation grants.

• Competing interests BW reports research support by Repare Therapeutics, outside of the current work. CAA reports clinical trial funding paid to the institution from AstraZeneca; funding paid to the institution from BMS and SELLAS Life Sciences Group; consulting fees (advisory board) from Eisai/Merck, Roche/Genentech, Abbvie, AstraZeneca/Merck, and Repare Therapeutics; advisory board participation (no fee) for Blueprint Medicine; and leadership/fiduciary roles for the GOG Foundation Board of Directors (travel cost reimbursem*nt) and NRG Oncology Board of Directors (unpaid). DZ reports institutional grants from Genentech, AstraZeneca, BMS, SELLAS Life Sciences Group, and Plexxikon; personal fees from Genentech, AstraZeneca, Xencor, Memgen, Synthekine, Celldex, and Hookipa; and stock options from Immunos, Accurius, Mana Therapeutics, and Calidi Biotherapeutics, outside of the submitted work. DZ is also an inventor on a patent related to the use of oncolytic Newcastle disease virus for cancer therapy. YLL reports research funding from AstraZeneca, GSK, and Repare Therapeutics. NRA-R reports research funding paid to the institution from GRAIL. ML reports research funding paid to the institution from KCI/Acelity, ad-hoc speaker for Intuitive Surgical, and advisory board participation for JnJ/Ethicon and Takeda. VM reports advisory board participation (unpaid) for Eisai, Merck, Clovis, Faeth, Duality, Morphyes, Karyopharm, Novartis, Lilly, and Immunocore. CFF reports participation in the scientific advisory boards for Merck (LYNK-002) and Genentech (MyPathway) without compensation, consulting for Seagen and Bristol Myers Squibb, and institutional research funds from Genentech/Roche, Bristol Myers Squibb, Merck, AstraZeneca, and Daiichi. SC serves as a consultant for AstraZeneca.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.